Clinical Relevance of the Serial Measurement of Krebs von den Lungen-6 Levels in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease

Krebs von den Lungen-6 (KL-6) levels measured at baseline have been reported as a circulating biomarker useful for the detection, evaluation of severity and assessment of risk of the progression of interstitial lung disease (ILD) in patients with systemic sclerosis (SSc). In this retrospective study...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yuichiro Shirai, Ryosuke Fukue, Yuko Kaneko, Masataka Kuwana
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	biomarker immunomodulatory treatment interstitial lung disease pneumoprotein systemic sclerosis scleroderma Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/49ce8a3fa3854df4b53b71ba526d6016
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:49ce8a3fa3854df4b53b71ba526d6016
record_format	dspace
spelling	oai:doaj.org-article:49ce8a3fa3854df4b53b71ba526d60162021-11-25T17:20:40ZClinical Relevance of the Serial Measurement of Krebs von den Lungen-6 Levels in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease10.3390/diagnostics111120072075-4418https://doaj.org/article/49ce8a3fa3854df4b53b71ba526d60162021-10-01T00:00:00Zhttps://www.mdpi.com/2075-4418/11/11/2007https://doaj.org/toc/2075-4418Krebs von den Lungen-6 (KL-6) levels measured at baseline have been reported as a circulating biomarker useful for the detection, evaluation of severity and assessment of risk of the progression of interstitial lung disease (ILD) in patients with systemic sclerosis (SSc). In this retrospective study, longitudinal changes in serum KL-6 levels over 2 years were examined in 110 patients with SSc using prospectively collected cohort data. Serum KL-6 levels fluctuated in a significant proportion of the patients but remained stable in the remaining patients. A wide range of variability of longitudinal KL-6 levels was associated with the presence of ILD, diffuse cutaneous SSc, positive anti-topoisomerase I antibodies, negative anticentromere antibodies, increased ILD extent on high-resolution computed tomography, extensive disease, low pulmonary function parameters, high KL-6 levels at baseline and immunomodulatory treatment. Extensive disease was consistently identified as an independent factor associated with variability in KL-6 levels in different models of multiple regression analysis. We failed to demonstrate correlations between trends for KL-6 level changes during the 6 months after SSc diagnosis and ILD progression over 2 years in patients with SSc-ILD. Serum KL-6 levels fluctuate in SSc patients with ILD, especially in those with extensive disease, but the clinical utility of a serial KL-6 level measurement remains uncertain.Yuichiro ShiraiRyosuke FukueYuko KanekoMasataka KuwanaMDPI AGarticlebiomarkerimmunomodulatory treatmentinterstitial lung diseasepneumoproteinsystemic sclerosissclerodermaMedicine (General)R5-920ENDiagnostics, Vol 11, Iss 2007, p 2007 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	biomarker immunomodulatory treatment interstitial lung disease pneumoprotein systemic sclerosis scleroderma Medicine (General) R5-920
spellingShingle	biomarker immunomodulatory treatment interstitial lung disease pneumoprotein systemic sclerosis scleroderma Medicine (General) R5-920 Yuichiro Shirai Ryosuke Fukue Yuko Kaneko Masataka Kuwana Clinical Relevance of the Serial Measurement of Krebs von den Lungen-6 Levels in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease
description	Krebs von den Lungen-6 (KL-6) levels measured at baseline have been reported as a circulating biomarker useful for the detection, evaluation of severity and assessment of risk of the progression of interstitial lung disease (ILD) in patients with systemic sclerosis (SSc). In this retrospective study, longitudinal changes in serum KL-6 levels over 2 years were examined in 110 patients with SSc using prospectively collected cohort data. Serum KL-6 levels fluctuated in a significant proportion of the patients but remained stable in the remaining patients. A wide range of variability of longitudinal KL-6 levels was associated with the presence of ILD, diffuse cutaneous SSc, positive anti-topoisomerase I antibodies, negative anticentromere antibodies, increased ILD extent on high-resolution computed tomography, extensive disease, low pulmonary function parameters, high KL-6 levels at baseline and immunomodulatory treatment. Extensive disease was consistently identified as an independent factor associated with variability in KL-6 levels in different models of multiple regression analysis. We failed to demonstrate correlations between trends for KL-6 level changes during the 6 months after SSc diagnosis and ILD progression over 2 years in patients with SSc-ILD. Serum KL-6 levels fluctuate in SSc patients with ILD, especially in those with extensive disease, but the clinical utility of a serial KL-6 level measurement remains uncertain.
format	article
author	Yuichiro Shirai Ryosuke Fukue Yuko Kaneko Masataka Kuwana
author_facet	Yuichiro Shirai Ryosuke Fukue Yuko Kaneko Masataka Kuwana
author_sort	Yuichiro Shirai
title	Clinical Relevance of the Serial Measurement of Krebs von den Lungen-6 Levels in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease
title_short	Clinical Relevance of the Serial Measurement of Krebs von den Lungen-6 Levels in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease
title_full	Clinical Relevance of the Serial Measurement of Krebs von den Lungen-6 Levels in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease
title_fullStr	Clinical Relevance of the Serial Measurement of Krebs von den Lungen-6 Levels in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease
title_full_unstemmed	Clinical Relevance of the Serial Measurement of Krebs von den Lungen-6 Levels in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease
title_sort	clinical relevance of the serial measurement of krebs von den lungen-6 levels in patients with systemic sclerosis-associated interstitial lung disease
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/49ce8a3fa3854df4b53b71ba526d6016
work_keys_str_mv	AT yuichiroshirai clinicalrelevanceoftheserialmeasurementofkrebsvondenlungen6levelsinpatientswithsystemicsclerosisassociatedinterstitiallungdisease AT ryosukefukue clinicalrelevanceoftheserialmeasurementofkrebsvondenlungen6levelsinpatientswithsystemicsclerosisassociatedinterstitiallungdisease AT yukokaneko clinicalrelevanceoftheserialmeasurementofkrebsvondenlungen6levelsinpatientswithsystemicsclerosisassociatedinterstitiallungdisease AT masatakakuwana clinicalrelevanceoftheserialmeasurementofkrebsvondenlungen6levelsinpatientswithsystemicsclerosisassociatedinterstitiallungdisease
_version_	1718412468986839040

Clinical Relevance of the Serial Measurement of Krebs von den Lungen-6 Levels in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease

Ejemplares similares